Elucidating cellular heterogeneity among cancer stem cells by Raman Spectroscopy
Elucidating cellular heterogeneity among cancer stem cells by Raman Spectroscopy
批准号:
8916059
负责人:
FARIBA BEHBOD
金额:
$14.51万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-01 至 2017-08-31
关键词:
8q24AwardBiochemicalBiological AssayBreast Cancer CellBreast Cancer ModelCD44 geneCancer RelapseCell SeparationCellsCharacteristicsClinicalClonal EvolutionCluster AnalysisCommunitiesDataDepartment of DefenseDevelopmentDiscriminant AnalysisDiscriminationDrug resistanceEpigenetic ProcessExhibitsFlow CytometryFutureGenomicsGoalsHealthHeterogeneityHumanIn Situ HybridizationIndividualIndolentKnockout MiceLasersLeast-Squares AnalysisLifeLightMalignant NeoplasmsMammary NeoplasmsMethodologyMethodsMolecularMolecular ProfilingMusMutationOutcomePatientsPhotonsRaman Spectrum AnalysisResearchResearch DesignResistanceResolutionRoleSorting - Cell MovementSourceSpecificitySpectrum AnalysisSurfaceTechnologyTherapeuticTimeTransplantationTumorigenicityanti-cancer therapeuticbasecancer cellcancer stem cellcancer therapychemotherapydesignextracellularin vivomalignant breast neoplasmneoplastic cellnew technologyphysical propertypreventtherapeutic developmenttooltumortumorigenic
中文摘要
描述(由申请人提供):乳腺癌细胞通常表现出功能和表型的异质性。细胞异质性可能是促进癌症复发的耐药和休眠的来源。肿瘤细胞异质性的一个来源可能是肿瘤干细胞的存在。基于这一假设,致瘤性CSCs(此处称为肿瘤起始细胞(tic))“分化”为非致瘤性癌细胞,形成层次结构和肿瘤细胞异质性。乳腺tic通过表达独特的细胞外表面标记物如CD44hi/CD24lo来鉴定。现在认为,即使是tic也可能通过克隆进化表现出细胞异质性。为了研究乳腺tic的异质性,我们使用了拉曼光谱(RS)。RS能够表征活tic的细胞内分子组成。通过进行RS,我们证明了基于独特的细胞内分子成分的表达,活的tic表现出肿瘤间和肿瘤内的异质性。基于这些数据,我们假设tic是异质的,拉曼镊子光谱(RTS)可能是一种分类和功能评估具有独特细胞内分子谱(imp)的tic群的致瘤潜力的方法。我们的长期目标是识别和根除
英文摘要
DESCRIPTION (provided by applicant): Breast cancer cells often exhibit functional and phenotypic heterogeneity. Cellular heterogeneity may be the source of drug resistance and dormancy promoting cancer relapse. One source of tumor cell heterogeneity may be the existence of cancer stem cells. Based on this hypothesis, the tumorigenic CSCs, herein referred to as tumor initiating cells (TICs), "differentiate" into non-tumorigenic cancer cells creating a hierarchical organization and tumor cell heterogeneity. Breast TICs have been identified by the expression of unique extracellular surface markers such as CD44hi/CD24lo. It is now believed that even TICs may exhibit cellular heterogeneity through clonal evolution. In order to study heterogeneity among breast TICs, we utilized Raman Spectroscopy (RS). RS enables the characterization of intracellular molecular composition of live TICs. By performing RS, we demonstrated that live TICs exhibited both inter- and intra-tumoral heterogeneity based on the expression of a unique intracellular molecular component. Based on these data, we hypothesize that TICs are heterogeneous and Raman Tweezer Spectroscopy (RTS) may be a method by which to sort and functionally evaluate the tumorigenic potential of TICs groups that exhibit unique intracellular molecular profiles (IMPs). Our long-term goal is to identify and eradicate the
most resistant, dormant, and aggressive breast TICs in order to prevent cancer relapse. Our objective is to characterize heterogeneity among TICs by IMP using RTS. Our Rationale is that so far, TICs have been isolated and characterized by the expression of unique surface markers. However, a methodology for isolation and characterization of TICs based on combined extracellular and IMP has not been evaluated. RS is a vibrational spectroscopy. Photons of the laser light are absorbed by live cells and then reemitted, providing spectral profiles (wavelengths) that represent the intracellular biochemical signatures of living cells. RTS will be combined with advanced mathematical tools to quantify characteristic IMPs of TICs non-invasively, with high specificity and rapidly. RTS permits sorting cells according to their IMPs. The trapped cells will then be functionally evaluated for their tumorigenic potential by limiting dilution transplantation assays. These studies will provide the basis for future molecular characterization of the most aggressive and indolent breast TICs and design of therapeutic strategies for their eradiation.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Identifying the Molecular and Cellular Basis of Invasive Phenotype in Human DCIS
-
批准号:9311984
-
项目类别:
-
资助金额:$57.63万
-
财政年份:2017
-
负责人:FARIBA BEHBOD
-
依托单位:
Elucidating cellular heterogeneity among cancer stem cells by Raman Spectroscopy
-
批准号:8758098
-
项目类别:
-
资助金额:$17.49万
-
财政年份:2014
-
负责人:FARIBA BEHBOD
-
依托单位:
Progression of DCIS to invasive breast cancer through CCR2 chemokine signaling
-
批准号:9093752
-
项目类别:
-
资助金额:$41.23万
-
财政年份:2013
-
负责人:FARIBA BEHBOD
-
依托单位:
Progression of DCIS to invasive breast cancer through CCR2 chemokine signaling
-
批准号:8579298
-
项目类别:
-
资助金额:$41.34万
-
财政年份:2013
-
负责人:FARIBA BEHBOD
-
依托单位:
Progression of DCIS to invasive breast cancer through CCR2 chemokine signaling
-
批准号:9297227
-
项目类别:
-
资助金额:$41.35万
-
财政年份:2013
-
负责人:FARIBA BEHBOD
-
依托单位:
Progression of DCIS to invasive breast cancer through CCR2 chemokine signaling
-
批准号:8853250
-
项目类别:
-
资助金额:$41.41万
-
财政年份:2013
-
负责人:FARIBA BEHBOD
-
依托单位:
ROLE OF MIR146B IN SURVIVAL & SELF RENEWAL OF MAMMARY ALVEOLAR PROGENITOR CELLS
-
批准号:8360688
-
项目类别:
-
资助金额:$2.95万
-
财政年份:2011
-
负责人:FARIBA BEHBOD
-
依托单位:
Role of Cancer Stem Cells in Malignant Progression of Ductal Carcinoma in Situ.
-
批准号:7672069
-
项目类别:
-
资助金额:$11.91万
-
财政年份:2007
-
负责人:FARIBA BEHBOD
-
依托单位:
Role of Cancer Stem Cells in Malignant Progression of Ductal Carcinoma in Situ.
-
批准号:7811251
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2007
-
负责人:FARIBA BEHBOD
-
依托单位:
Role of Cancer Stem Cells in Malignant Progression of Ductal Carcinoma in Situ.
-
批准号:7847705
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2007
-
负责人:FARIBA BEHBOD
-
依托单位:
Role of Cancer Stem Cells in Malignant Progression of Ductal Carcinoma in Situ.
-
批准号:7418975
-
项目类别:
-
资助金额:$1.7万
-
财政年份:2007
-
负责人:FARIBA BEHBOD
-
依托单位:
Role of Cancer Stem Cells in Malignant Progression of Ductal Carcinoma in Situ.
-
批准号:7250765
-
项目类别:
-
资助金额:$13.61万
-
财政年份:2007
-
负责人:FARIBA BEHBOD
-
依托单位:
Role of Cancer Stem Cells in Malignant Progression of Ductal Carcinoma in Situ.
-
批准号:8079455
-
项目类别:
-
资助金额:$24.15万
-
财政年份:2007
-
负责人:FARIBA BEHBOD
-
依托单位:
Stem Cells in Normal Mammary Development and Cancer
-
批准号:6737510
-
项目类别:
-
资助金额:$5.65万
-
财政年份:2003
-
负责人:FARIBA BEHBOD
-
依托单位:
Stem Cells in Normal Mammary Development and Cancer
-
批准号:6891946
-
项目类别:
-
资助金额:$5.75万
-
财政年份:2003
-
负责人:FARIBA BEHBOD
-
依托单位:
Stem Cells in Normal Mammary Development and Cancer
-
批准号:6646793
-
项目类别:
-
资助金额:$5.63万
-
财政年份:2003
-
负责人:FARIBA BEHBOD
-
依托单位:
海外基金